Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

The objective of this study was to evaluate whether interleukin-2 (IL-2) receptor expression on CD56(bright) natural killer (NK) cells predicted CD56(bright) NK cell expansion and therapeutic response to daclizumab (DAC) in multiple sclerosis (MS). DAC exposure, CD56(bright) NK cell counts, IL-2 rec...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis 2011-12, Vol.17 (12), p.1441-1448
Hauptverfasser:	Sheridan, James P, Zhang, Ying, Riester, Katherine, Tang, Meina T, Efros, Lyubov, Shi, Jia, Harris, Jeffrey, Vexler, Vladimir, Elkins, Jacob S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use CD56 Antigen - analysis Cell Proliferation - drug effects Humans Immunoglobulin G - therapeutic use Interleukin-2 Receptor alpha Subunit - metabolism Interleukin-2 Receptor beta Subunit - metabolism Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Multiple Sclerosis - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!